FASB ASU 2025-12: How to Calculate Diluted EPS in a Loss Year with Options, Warrants, and Convertible Notes

Losing money can still dilute your shareholders more than you think​

Here's a scenario that trips up a lot of first-time CFOs and finance-savvy founders: your company posted a net loss for the year, so you assume diluted earnings per share (EPS) is a non-issue — after all, "diluted loss per share" sounds like it should just equal basic loss per share, since adding more shares to a loss can't make things worse, right?

That assumption has been wrong for years, and FASB just rewrote the rulebook to make sure everyone treats it consistently. If your company has outstanding stock options, warrants, or convertible notes and you're anywhere near a loss year, a new accounting standard — ASU 2025-12 — changes exactly how you're supposed to calculate diluted EPS, and getting it wrong can mean restating your financial statements later.

This matters well beyond public companies. Any startup or growing business that issues equity compensation, raises convertible debt, or grants warrants to lenders and investors eventually has to produce GAAP-compliant financials — for an audit, a bank covenant, a Series A term sheet, or an eventual exit. Understanding this change now saves you (and your accountant) a scramble later.

A 30-second refresher on diluted EPS​

Public companies — and many private companies that follow GAAP for lenders or investors — report two versions of earnings per share:

• Basic EPS: net income (or loss) divided by the weighted-average number of common shares actually outstanding.
• Diluted EPS: the same calculation, but adjusted to assume that every "potential" common share — stock options, warrants, convertible notes, convertible preferred stock — actually converted into common stock.

The idea is that diluted EPS shows shareholders the worst-case dilution: what earnings per share would look like if everyone with the right to become a shareholder exercised that right. Two methods do the heavy lifting:

• Treasury stock method (options and warrants): assumes the company collects the exercise proceeds and uses that cash to buy back shares at the average market price. If the exercise price is below the average share price — the options are "in the money" — more shares get issued than can be bought back, and the difference dilutes EPS.
• If-converted method (convertible notes and convertible preferred stock): assumes the instrument converted into common stock at the start of the period (or issuance date), while adding back any related interest expense or preferred dividends to the numerator.

For a profitable company, running these calculations is mechanical. For a company with a net loss, it gets murkier — and that murkiness is exactly what FASB just cleaned up.

What actually changed under ASU 2025-12​

In December 2025, FASB issued ASU 2025-12, a package of 33 "Codification Improvements" — mostly small clarifications and corrections to existing GAAP. Buried in that package is Issue 4, which directly rewrites how companies handle diluted EPS when they report a loss from continuing operations.

Before the update, two provisions in the EPS guidance quietly contradicted each other:

1. One said that instruments settleable in either cash or stock should be reflected in diluted EPS "if dilutive," full stop — regardless of whether the company had income or a loss.
2. Another said potential common shares would "always" be antidilutive (and therefore excluded) during a loss period.

In practice, that contradiction meant different companies — and sometimes different auditors — reached different answers for the same fact pattern, especially for instruments classified as liabilities and remeasured through earnings each period, like many warrants issued alongside venture debt or SPAC transactions.

ASU 2025-12 resolves it by clarifying that during a loss from continuing operations, including potential common shares in diluted EPS is generally — not automatically — antidilutive. Companies must actually run the math: evaluate the combined effect on both the numerator (net income or loss, adjusted for things like reversing a fair-value gain on liability-classified warrants) and the denominator (shares added under the treasury stock or if-converted method). If that combined effect makes the loss per share larger in magnitude, the instrument is dilutive and must be included — even though the company lost money.

A worked example​

Here's the kind of scenario the new guidance is aimed at:

• Entity A reports a $5 million net loss for the year, with 10 million weighted-average shares outstanding.
• Basic loss per share: $(0.50).
• The company has outstanding warrants to purchase 500,000 shares at $2.00/share. The warrants are classified as a liability (common when they include cash-settlement or down-round features) and are remeasured to fair value each period. This year, the fair-value remeasurement produced a $0.5 million gain, recorded in earnings, because the stock price rose.
• Average stock price during the year was $2.50 — meaning the warrants are in the money.

Under the treasury stock method, the warrants add roughly 100,000 net new shares to the denominator (the shares issued minus the shares theoretically repurchased with the $2.00 exercise proceeds at a $2.50 average price). But you also have to adjust the numerator: because the warrant gain wouldn't exist if the warrants had already been exercised (they'd no longer be a remeasured liability), you reverse that $0.5 million gain out of net income, pushing the loss to $5.5 million.

Run the math and diluted loss per share comes out to $(0.54) — a *bigger* loss per share than the$(0.50) basic figure, meaning the warrants are dilutive and must be included in diluted EPS, despite the year being a loss. Under the old, ambiguous guidance, plenty of companies would have simply assumed a loss year means no dilution and skipped this analysis entirely.

Who this actually affects​

If your company is privately held and never produces GAAP financial statements, this change won't touch your day-to-day. But it matters directly if you're in any of these situations:

• You're raising a priced round or have convertible notes/SAFEs on your cap table that will eventually convert, and investors or their counsel expect GAAP-compliant EPS disclosures as part of diligence or reporting covenants.
• You've issued warrants — to a lender as part of a venture debt facility, to an advisor, or as part of a prior fundraise — especially any warrants with cash-settlement, put, or down-round features that push them into liability classification under ASC 815.
• You're preparing for an audit (required by many institutional lenders, SBA-backed loans above certain thresholds, or as a precondition to a future IPO or acquisition) and your auditor will be applying this guidance to prior-period comparatives.
• You're a finance team at a growth-stage company that already reports diluted EPS and has had a loss year at some point — which describes a huge share of venture-backed companies.

When it takes effect, and why the timing matters now​

ASU 2025-12 is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted. Most of the 33 issues in the update can be adopted prospectively or retrospectively, company by company, issue by issue — but the diluted EPS clarification (Issue 4) is the exception. It must be applied retrospectively, meaning that once you adopt it, you go back and recast diluted EPS for every prior period presented in your financial statements.

That retrospective requirement is the real planning trigger. If your company has liability-classified warrants or convertible instruments and has had even one loss year in the comparative periods you'll present, you (or your outside accountant) need to rerun the numerator-and-denominator analysis for those historical periods, not just the current one. Waiting until the deadline to figure this out is how restatements happen.

What to do before this hits your financials​

1. Inventory your dilutive instruments. List every option pool grant, warrant, convertible note, and convertible preferred round still outstanding, and note which are liability-classified versus equity-classified — that classification determines whether a numerator adjustment applies.
2. Flag any loss periods in your reporting history. If you'll present multi-year comparatives once you adopt the standard, identify every period where you reported a net loss from continuing operations; those are the periods that need the combined numerator/denominator recalculation.
3. Loop in your accountant or auditor early. This is a genuinely technical calculation — worth confirming with a CPA rather than estimating it yourself, especially for the treasury stock and if-converted mechanics on liability-classified instruments.
4. Keep your underlying cap table and instrument terms in clean, structured records. The inputs to this calculation — exercise prices, share counts, conversion ratios, fair-value remeasurement history — are only as reliable as your books. If those numbers live in scattered spreadsheets instead of a single source of truth, reconstructing a prior-period EPS calculation gets painful fast.

Keep Your Financial Records Audit-Ready​

Whether or not diluted EPS ever appears on your financial statements, this update is a good reminder that clean, well-documented books make every downstream accounting exercise — audits, EPS calculations, cap table reconciliations — faster and less error-prone. Beancount.io provides plain-text accounting that's transparent, version-controlled, and easy to hand to an auditor or accountant without untangling someone else's spreadsheet logic. Check out the documentation to see how a version-controlled ledger keeps your equity and debt instruments — and everything else — reconciled and ready.